Q/C Technologies, Inc. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Q/C Technologies, Inc. (QCLS) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of -$4.67 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2026-04-15
- Q/C Technologies, Inc. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2024 was -$4.67M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|
| 2024-12-31 | -$4.67M 10-K · filed 2026-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |